文献速递眼整形与眼眶角膜与眼表疾病

程序性细胞死亡配体1和2在结膜浸润性鳞状细胞癌中的表达及治疗意义

Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
PubMed 文献 · Am J Ophthalmol · 2019-01-08

该回顾性病例系列分析了18例眼表或眼附属器浸润性鳞状细胞癌标本,采用免疫组化检测PD-L1、PD-L2、CD8和p16表达。所有肿瘤(100%)表达PD-L1,其中39%为高水平;仅50%肿瘤低水平表达PD-L2。肿瘤细胞PD-L1表达与瘤内CD8阳性细胞毒性T淋巴细胞(P<.01)及周围基质CD8阳性细胞(P=.04)相关。部分高表达PD-L1和CD8的肿瘤可能对免疫检查点抑制治疗有反应。

要点

  • 所有18例结膜浸润性鳞癌均表达PD-L1,39%为高水平表达。
  • 仅50%肿瘤低水平表达PD-L2,PD-L1表达与CD8阳性T细胞浸润相关。
  • 高表达PD-L1和CD8的肿瘤可能从免疫检查点抑制治疗中获益。

核心结论

  • 部分眼表浸润性结膜鳞状细胞癌高表达PD-L1并伴有CD8阳性T细胞浸润,可能对免疫检查点抑制治疗有反应。

研究设计与样本

  • 回顾性病例系列,纳入2014年1月1日至2017年1月1日期间马萨诸塞州总医院/马萨诸塞眼耳医院和Wills眼科医院病理档案中18例眼表或眼附属器浸润性鳞状细胞癌病例。
  • 采用标准化方法对PD-L1、PD-L2、CD8和p16进行免疫组化染色和分级。

主要发现

  • PD-L1和PD-L2在肿瘤细胞上程度不等地表达,也在部分基质细胞和内皮细胞上表达;对照结膜标本中基质和内皮细胞也可见表达。
  • 肿瘤细胞PD-L1和PD-L2表达位于细胞膜。
  • 全部18例(100%)肿瘤表达PD-L1:7例(39%)高水平,3例(17%)中等水平,8例(44%)低水平。
  • 仅9例(50%)肿瘤表达PD-L2,且均为低水平。
  • 肿瘤细胞PD-L1表达与瘤内CD8阳性细胞毒性T淋巴细胞存在相关(P<.01),与周围基质中CD8阳性细胞存在相关(P=.04)。

临床怎么用

  • 对结膜浸润性鳞状细胞癌可考虑检测PD-L1和CD8表达,以筛选可能适合免疫检查点抑制治疗的患者。

局限性

  • 回顾性病例系列,样本量较小(18例),未报告随访或治疗反应数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Novel cancer immunotherapies, called immune checkpoint inhibitors, have demonstrated clinical efficacy in the treatment of squamous cell carcinomas of the head and neck. Tissue expression of programmed cell death 1 ligand 1 (PD-L1) and programmed cell death 1 ligand 2 (PD-L2) has been shown to predict tumor response to these drugs. We examine the expression of prognostic immune biomarkers, PD-L1 and PD-L2, in invasive ocular surface squamous neoplasia. DESIGN: Retrospective case series. METHODS: Eighteen cases of ocular surface or ocular adnexal invasive squamous cell carcinomas were identified in pathology case files of the Massachusetts General Hospital/Massachusetts Eye and Ear Infirmary and at the Wills Eye Hospital accessioned between January 1, 2014 and January 1, 2017. Immunohistochemical staining for PD-L1, PD-L2, CD8, and p16 was performed and graded in a standardized fashion. RESULTS: PD-L1 and PD-L2 were expressed on tumor cells to varying degrees, and also on some stromal cells and endothelial cells. Stromal and endothelial cell expression was also seen in control conjunctival specimens. Tumor expression of PD-L1 and PD-L2 was present on the cell membranes. All 18 (100%) of the tumors expressed PD-L1: 7 (39%) expressed a high level, 3 (17%) expressed a medium level, and 8 (44%) expressed a low level. Only 9 (50%) tumors expressed PD-L2 and it was at a low level. The expression of PD-L1 in tumor cells correlated with the presence of CD8-positive cytotoxic T lymphocytes among tumor cells (P < .01) and with the presence of CD8-positive cells in the surrounding stroma (P = .04). CONCLUSIONS: A subset of ocular invasive conjunctival squamous carcinomas express high levels of PD-L1 and CD8 and therefore may respond therapeutically to immune checkpoint inhibition.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wolkow N, Jakobiec FA, Afrogheh AH, et al. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications. Am J Ophthalmol. 2019. PMID: 30633894. doi:10.1016/j.ajo.2018.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。